What is Faeth Therapeutics?
Faeth Therapeutics operates at the intersection of precision medicine and oncology, utilizing AI-driven computational biology to map metabolic vulnerabilities in tumor cells. By integrating targeted therapeutics with precision nutrition, the company aims to disrupt traditional cancer treatment paradigms. Its market position is defined by a unique focus on metabolic reprogramming, a frontier in therapeutic development that seeks to starve cancer cells while preserving patient health. As a clinical-stage entity, Faeth Therapeutics is currently transitioning from foundational research to advanced clinical validation, positioning itself as a high-value asset in the broader life sciences sector.
How much funding has Faeth Therapeutics raised?
Faeth Therapeutics has raised a total of $92M across 3 funding rounds:
Angel/Seed
$20M
Series A
$47M
Other Financing Round
$25M
Angel/Seed (2022): $20M with participation from Future Ventures, S2G Ventures, and Khosla Ventures
Series A (2022): $47M led by Khosla Ventures, S2G Ventures, and Future Ventures
Other Financing Round (2025): $25M supported by S2G Ventures, Digitalis Ventures, Khosla Ventures, and Future Technologies
Key Investors in Faeth Therapeutics
Khosla Ventures
A prominent venture capital firm providing strategic advice and capital to breakthrough technology companies, with a deep focus on health, AI, and sustainable innovation.
S2G Ventures
A multi-stage investment firm specializing in the food and agriculture supply chain, identifying inflection points where innovation can drive systemic health improvements.
Future Ventures
A venture capital firm led by experienced investors focused on backing mission-driven founders and disruptive technologies that have the potential to reinvent global industries.
What's next for Faeth Therapeutics?
With the recent influx of capital, Faeth Therapeutics is well-positioned to accelerate its clinical development pipeline and expand its computational research capabilities. The strategic focus will likely shift toward scaling its proprietary AI platforms and advancing lead candidates through rigorous human trials. Given the company's emphasis on metabolic vulnerabilities, future milestones will likely involve data-driven partnerships and the potential for expanded intellectual property portfolios. As the firm matures, the focus will remain on achieving clinical efficacy, which will be critical for future valuation milestones and potential long-term commercialization strategies in the global oncology market.
See full Faeth Therapeutics company page
